Demand risk from customer investment and fluctuations in industrial sectors
First written in FY2022. 4 of 12 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2020: 60 of 75 companies on the "Worse" side.
21 other companies' latest entry also says "Mitigated".
- FY2026-H1MitigatedAnnual report
「In the Healthcare Business, shipments to a new customer, a high-performance PET manufacturer, reached full scale, resulting in higher revenue both against the forecast and year on year.」
Healthcare business sales increased both versus the forecast and year on year as shipments to new customers gained momentum, reducing the impact on this business of the demand risk that had materialized through declining demand from existing customers and other factors. - FY2025MaterialisedAnnual report
「In the healthcare business, sales declined year on year because demand from existing customers decreased and finalizing delivery specifications in transactions with new customers took time, causing sales originally planned for the period to be pushed back to the following fiscal year and beyond.」
Due to lower demand from existing customers and delays in finalizing delivery specifications for new customers, healthcare business sales were pushed back from the plan to the following fiscal year and beyond, resulting in a 23.0% year-on-year decline. - FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new business risks or material changes to the business risks described in the annual securities report for the previous fiscal year.」
No significant changes are reported in demand risk stemming from customer investment and industrial-sector fluctuations. - FY2025-Q1MitigatedAnnual report
「The Healthcare Business progressed broadly in line with plan. The New Business segment also progressed broadly in line with plan. Raicol’s revenue grew steadily and was slightly above plan.」
The healthcare and new business areas progressed broadly in line with plan, while Raicol's sales slightly exceeded plan. The impact of customer demand and inventory trends is limited in the businesses covered by this filing. - FY2024MaterialisedAnnual report
「In the healthcare business, shipments to major customers remained sluggish due to the slowdown in the Chinese economy and other factors, and sales for the business in the consolidated fiscal year were ¥1,592 million.」
Lower customer demand resulting from the slowdown in the Chinese economy and other factors materialized in the healthcare business as sluggish shipments and full-year sales of ¥1,592 million. - FY2024-Q3MaterialisedAnnual report
「In the healthcare business, results recovered temporarily in the second quarter, but fell slightly below the initial forecast in the third quarter. In the new business areas, third-quarter sales also fell below the initial forecast.」
The demand risk related to customer inventory and investment trends and other factors re-emerged, with third-quarter results in both the healthcare business and new business areas falling below the initial forecast. - FY2024-Q2MitigatedAnnual report
「In the healthcare business, results recovered in the second quarter and exceeded plan for the cumulative second-quarter period.」
The healthcare business, which fell below plan in the first quarter due to inventory adjustments at customers and other factors, recovered in the second quarter and exceeded plan on a cumulative basis. - FY2024-Q1MaterialisedAnnual report
「In the healthcare business, inventory adjustments at major customers that have continued since the fourth quarter of the previous fiscal year caused results to fall slightly below plan.」
Inventory adjustments at major customers continued from the fourth quarter of the previous fiscal year, causing healthcare business sales to fall slightly below plan. The risk that customer investment and inventory trends would affect demand has materialized in the results. - FY2023-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
No significant changes are reported in demand risk stemming from customer investment and industrial-sector fluctuations. - FY2023-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
No significant changes are reported in demand risk stemming from customer investment and industrial-sector fluctuations. - FY2023-Q1RestatedAnnual report
「During the three months ended March, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
No significant changes are reported in demand risk stemming from customer investment and industrial-sector fluctuations. - FY2022First statedAnnual report
「Demand for the products we provide tends to follow customers' advance investment in the development of next-generation products, and delays in next-generation investment and product conversion by customer companies may adversely affect our financial condition and operating results.」
Although customers are diversified across several industries, including medical equipment, semiconductors and lasers, the company has newly specified the risk that customer investment in next-generation products and fluctuations across entire industries may affect demand. The likelihood of occurrence is assessed as high and the degree of impact as significant.